A Young Patient with Mantle Cell Lymphoma has been Cured by Myeloablative Hematopoietic Stem Cell Transplantation

Al-Enazi W, AlGarni A, Al-Sagheir A and Al-Anazi KA

Department of Hematology and Hematopoietic Stem Cell Transplantation, King Fahad Specialist Hospital, Dammam,Saudi Arabia

^*Correspondance to: Al-Anazi KA 

 PDF  Full Text Case Report | Open Access

Abstract:

The diagnosis of Mantle Cell Lymphoma (MCL) is rarely made in young adults as the disease is most commonly encountered in middle age and elderly individuals. The currently available therapeutic modalities including autologous Hematopoietic Stem Cell Transplantation (HSCT) are not curative. Allogeneic HSCT with Reduced-Intensity Conditioning (RIC) therapy is usually offered to transplant-eligible patients taking into consideration their old age and comorbid medical conditions. We report a young patient who failed to achieve Complete Remission (CR) of her MCL after receiving 8 cycles of intensive cytotoxic chemotherapy, commenced in August 2008, at King Fahad Specialist Hospital (KFSH) in Dammam, Saudi Arabia. Later on the patient had an allogeneic HSCT with myeloablative conditioning therapy performed at King Faisal Specialist Hospital and Research Center (KFSH-RC) in Riyadh in February 2009. During her follow-up at KFSH in Dammam, she developed hepatic Graft Versus Host Disease (GVHD) that was successfully treated with steroids and cyclosporine-A. Eighteen months after her allograft, the patient had complete resolution of her residual disease. Her MCL is still in CR more than 6 years after her HSCT.

Keywords:

Mantle cell lymphoma; Cytotoxic chemotherapy; Hematopoietic stem cell transplantation; Myeloablative conditioning; Graft versus host disease

Cite the Article:

Al-Enazi W, AlGarni A, Al-Sagheir A, Al- Anazi KA. A Young Patient with Mantle Cell Lymphoma has been Cured by Myeloablative Hematopoietic Stem Cell Transplantation. Clin Oncol. 2017; 2: 1222.